ntroduction
In today’s world of advanced medical treatments and cutting-edge therapies, the pricing of healthcare products can be a complex puzzle. One particular area of intrigue is the pricing of Cell and Gene Therapies (CAGTs), which stand apart from traditional medicines in their profound potential for lifelong cures and long-lasting improvements in patients’ lives. However, their unique nature poses a challenge to our conventional healthcare system, which typically operates on a pay-as-you-go basis, where patients continually pay for treatments that manage symptoms rather than addressing the root cause.
Let’s delve into this fascinating territory, exploring the intricate dynamics of CAGT pricing, the concept of surrogate endpoints, and the evolving landscape of healthcare assessment agencies.
CAGTs: A Different Ballgame
CAGTs are revolutionary. They hold the promise of not just alleviating symptoms but curing diseases for good. Take, for example, CRISPR Therapeutics/Vertex’s VCTX series for diabetes. If approved by the FDA, these therapies could represent a once-and-done cure. Contrast this with the current norm, where patients with diabetes continuously purchase insulin and undergo regular blood sugar tests. The difference is stark, but it raises a crucial question: How do we price these transformative therapies?
The Role of Surrogate Endpoints
One of the solutions to this pricing puzzle lies in the concept of “surrogate endpoints.” These serve as shortcuts to evaluate CAGTs when immediate, long-term results may not be evident. Picture this: you have a genetic condition, and a gene therapy aims to correct it. Rather than experiencing immediate improvements, the therapy might work silently in the background, much like maintaining a car to prevent future breakdowns.
Yet, there’s a challenge. As scientific understanding evolves and new ways of assessing therapies emerge, our regulations and payment systems may struggle to keep pace. This can result in insurance companies and pricing authorities hesitating to support these therapies without concrete proof of their long-term effectiveness. The waiting game can be especially challenging for smaller genetic therapy companies with limited resources, as they may require years of data collection before gaining approval.
In essence, surrogate endpoints offer a way to bridge the gap between the promise of gene therapies and the practicalities of our healthcare system. However, updating our healthcare framework to align with the latest scientific advancements remains a crucial task.
The European Perspective
In Europe, health technology assessment agencies (HTAs) play a pivotal role in deciding which healthcare products should be accessible to patients. They meticulously evaluate whether these products outperform existing options, address severe health issues, and provide value for the healthcare system.
CAGTs, with their potential for long-lasting benefits, can pose a conundrum. Some conditions may take years to show improvement or prevent further deterioration, making it impractical to wait decades for assessments. However, there’s a promising shift on the horizon. Starting in 2025, Europe will introduce a new system where these agencies collaborate to assess CAGTs. They may also incorporate real-world evidence gathered after approval based on surrogate endpoints to inform decisions across the European Union.
A Glimpse into the Future
The changes unfolding in Europe might soon influence the United States, where organizations like the Institute for Clinical and Economic Review (ICER) could adopt similar approaches. However, it’s important to note that not all CAGTs require surrogate endpoints, and the evaluation process can vary depending on the conditions they address.
Factors such as the age of the patient may also come into play. Younger patients may benefit more from one-time gene therapies, potentially influencing their value.
Beyond the Bottom Line
As we navigate the intricate intersection of healthcare and economics, it’s crucial to remember the broader implications. Money has undoubtedly driven economic progress and improved our quality of life. However, it has also led to the commoditization of many aspects of our existence. In our pursuit of financial gain, we must not lose sight of our responsibility to society.
Business schools can play a role by emphasizing corporate social responsibility, and schools should enhance civic education to preserve our shared humanity.
In a world that sometimes seems obsessed with the accumulation of wealth, it’s worth reflecting on the lessons of science fiction, like “Star Trek,” where the Ferengi race serves as a cautionary tale of prioritizing profit above all else. Let’s ensure we chart a different course and uphold our values as we navigate the exciting and challenging frontier of healthcare.
We welcome your thoughts and comments on this multifaceted issue. Together, let’s shape a future where cutting-edge therapies are accessible, affordable, and aligned with our shared values.
Sharetreck - Tracking Genomic Investments & clinical trials for HIV. 